Aerie Pharmaceuticals Inc (NASDAQ:AERI) announced the pricing of a registered underwritten public offering of $75 million of shares of its common stock at a …
Aerie Pharmaceuticals Inc (NASDAQ:AERI) shares jumped over 50%, after the glaucoma drug company announced positive top-line efficacy results from its Phase III “Mercury 1” …
Aerie Pharmaceuticals Inc’s (NASDAQ:AERI) pipeline drug Roclatan, a novel once-daily, quadruple-action eye drop being tested for its ability to lower intraocular pressure (IOP) …
Biotech stocks are looking to erase their losses over the past month today, as the iShares Nasdaq Biotechnology ETF (IBB) gained nearly 2%. Among the equities in …
Aerie Pharmaceuticals Inc (NASDAQ:AERI), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class glaucoma therapies, today announced the completion of …
Aerie Pharmaceuticals Inc (NASDAQ:AERI), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class glaucoma therapies, today announced that on March …
In a research report released Friday, Cantor analyst Caroline Corner reiterated a Buy rating on shares of Aerie Pharmaceuticals Inc (NASDAQ:AERI) with a price …
Aerie Pharmaceuticals Inc (NASDAQ:AERI), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class glaucoma therapies, today reported the successful 12-month …
Aerie Pharmaceuticals Inc (NASDAQ:AERI) skyrocketed over 93% in pre-market trading up to $34.85 after the pharmaceutical company reported positive data for its second …
Aerie Pharmaceuticals Inc (NASDAQ:AERI), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class glaucoma therapies, today reported the successful results …
